ADC Therapeutics
Rue Saint-Pierre 2,
Lausanne
1003
Tel: 1-212-616-4000
Website: http://www.adctherapeutics.com/
Email: info@adctherapeutics.com
192 articles about ADC Therapeutics
-
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
3/13/2024
ADC Therapeutics SA reported financial results for the fourth quarter and full year ended December 31, 2023, and provided business updates.
-
ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
3/6/2024
ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 5th Annual Healthy Altitudes Summit on Tuesday, March 12, at 7:30 a.m. MT.
-
ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024
3/6/2024
ADC Therapeutics SA announced that it will host a conference call and live webcast on Wednesday, March 13, 2024, at 8:30 a.m. ET to report financial results for the fourth quarter and year ended December 31, 2023, and provide business updates.
-
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting
3/5/2024
ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on its novel antibody drug conjugates (ADCs) have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, which will be held in San Diego, CA from April 5-10, 2024.
-
ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
2/27/2024
ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5 at 9:50 a.m. ET.
-
ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards
1/4/2024
ADC Therapeutics SA today announced that it received a notice from the New York Stock Exchange (NYSE) on January 2, 2024 that the Company has regained compliance with the continued listing minimum price criteria set forth in Section 802.01C of the NYSE Listed Company Manual and, as a result, will be removed from the NYSE’s noncompliant issuers list.
-
ADC Therapeutics Provides Business Updates - Jan 04, 2024
1/4/2024
During 2023, we took a number of decisive actions to help position the Company for success in 2024 and beyond. We prioritized our pipeline, strengthened our organization and implemented a disciplined capital allocation model to generate cost efficiencies.
-
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
12/12/2023
ADC Therapeutics SA announced initial results from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® in combination with rituximab demonstrated a high response rate in patients with relapsed or refractory follicular lymphoma.
-
ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
11/7/2023
ADC Therapeutics SA reported financial results for the third quarter 2023 and provided business updates.
-
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
11/7/2023
ADC Therapeutics SA announced that on October 10, 2023, it received a notice from the New York Stock Exchange that the Company is not in compliance with the continued listing minimum price criteria set forth in Section 802.01C of the NYSE Listed Company Manual, which requires listed companies to maintain an average closing share price of at least $1.00 over a consecutive 30 trading-day period.
-
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference 2023
11/6/2023
ADC Therapeutics SA announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 14th at 10:00 a.m. GMT.
-
ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023
10/24/2023
ADC Therapeutics SA announced that it will host a conference call and live webcast on Tuesday, November 7, 2023 at 8:30 a.m. ET to report financial results for the third quarter 2023 and provide business updates.
-
ADC Therapeutics to Participate in September 2023 Investor Conferences
9/5/2023
ADC Therapeutics SA announced that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in September.
-
ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)
8/30/2023
ADC Therapeutics SA (NYSE: ADCT) today announced that two ZYNLONTA® (loncastuximab tesirine-lpyl) abstracts have been accepted for presentation at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023), which will be held in Houston, Texas from September 6-9, 2023.
-
ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
8/1/2023
ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, August 8, 2023 at 8:30 a.m. EDT to report financial results for the second quarter 2023 and provide business updates.
-
Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
7/24/2023
Overland ADCT BioPharma, a joint venture of Overland Pharmaceuticals (CY) Inc. and ADC Therapeutics SA (NYSE: ADCT), today announced that the China National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for ZYNLONTA.
-
Following seven patient deaths in a Phase II study, ADC Therapeutics is discontinuing the development of its Zynlonta antibody-drug conjugate—combined with Rituxan—for diffuse large B-cell lymphoma.
-
Severe respiratory problems killed seven patients and affected five others, though the company said that most of these were likely unrelated to the drug.
-
ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
7/11/2023
ADC Therapeutics SA announced a voluntary pause in the enrollment of new patients in the Phase 2 LOTIS-9 clinical trial evaluating ZYNLONTA® and rituximab in unfit or frail patients with previously untreated diffuse large B-cell lymphoma.
-
ADC Therapeutics Announces Evolution of Board of Directors
6/15/2023
ADC Therapeutics SA announced the election of Robert W. Azelby to its Board of Directors.